Opicapone (Ongentys) is a selective and reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. It is used as an adjunctive treatment to levodopa/carbidopa for improving "off" periods in patients with Parkinson's disease.

Precautions for Opicapone (Ongentys) Use

Dosage and Administration

The standard recommended dose of opicapone is 50 mg once daily, to be taken orally before bedtime.

For patients with moderate hepatic impairment (Child-Pugh Class B), the dose should be reduced to 25 mg once daily.

Patients with severe hepatic impairment (Child-Pugh Class C) should avoid using this medication.

Fasting is required for 1 hour before and after taking the medication to ensure optimal drug absorption.

Medication Use in Special Populations

Pregnant women should use opicapone with caution, as animal studies have shown it may cause harm to the fetus.

Lactating women should weigh the benefits and risks before deciding whether to use this medication.

Elderly patients aged 65 years and above usually do not require dose adjustment, but close monitoring for adverse reactions is necessary.

Patients with end-stage renal disease (CLcr < 15 mL/min) should avoid using this medication.

Drug Interactions

Concomitant use of opicapone with non-selective monoamine oxidase (MAO) inhibitors (e.g., phenelzine, isocarboxazid) is strictly prohibited, as it may cause severe cardiovascular reactions.

This medication is also contraindicated in patients with a history of pheochromocytoma, paraganglioma, or other catecholamine-secreting tumors.

Dietary and Lifestyle Recommendations

Patients must strictly adhere to the requirement of fasting for 1 hour before and after taking the medication.

Since daytime somnolence may occur, driving or operating hazardous machinery should be avoided during the medication period.

It is recommended to maintain a regular daily routine and avoid sudden postural changes to prevent orthostatic hypotension.

Medication Monitoring for Opicapone (Ongentys)

Cardiovascular System Monitoring

When opicapone is used concomitantly with COMT-metabolized drugs (e.g., isoprenaline, adrenaline), close monitoring of heart rate, heart rhythm, and blood pressure changes is required.

Clinical observation should focus on potential risks such as arrhythmias, increased heart rate, and abnormal fluctuations in blood pressure.

Neurological Symptom Monitoring

During the medication period, regular assessment of dyskinesia is necessary, as approximately 20% of patients may experience the onset or worsening of dyskinesia.

At the same time, attention should be paid to episodes of daytime somnolence, especially when engaging in activities requiring high concentration such as driving.

If uncontrollable sleep attacks occur, consideration should be given to adjusting the treatment plan.

Psychiatric and Psychological Status Monitoring

Healthcare providers should regularly inquire about patients for the presence of psychotic symptoms such as hallucinations and delusions, with an incidence rate of approximately 3%.

Special attention should be paid to impulse control disorders such as pathological gambling, hypersexuality, and compulsive shopping, as these symptoms may resolve after discontinuing the medication.